PhD Scientific Days 2020

Neurosciences I. Posters

Effect of Intracerebroventricularly Injected Streptozotocin on the Cognitive Performance of Long-Evans Rats

Előadó neve

Gáspár, Attila, MSc

Előadó munkahelye

Semmelweis University Department of Pharmacology and Pharmacotherapy

Előadó telefonszáma

06707793789

Előadó e-mail címe

gasparattila910816@gmail.com

Az előadás címe

Effect of Intracerebroventricularly Injected Streptozotocin on the Cognitive Performance of Long-Evans Rats

Szerző(k) neve és munkahelye

Attila Gáspár, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Aliz Judit Ernyey, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Anna Bekő, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
Barbara Hutka, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Brigitta Tekla Tajti, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Bence Tamás Varga, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Zoltán Zádori, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
István Gyertyán, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest

Szekció

Neurosciences I. Posters

Language of the presentation

Hungarian

Section, first choice

Neurosciences

Section, second choice

Theoretical and Translational Medicine

Összefoglaló szövege

Brain insulin resistance is one of the molecular symptoms of Alzheimer’s disease (AD). In rats, intracerebroventricularly injected streptozotocin causes insulin resistance and produces many symptoms of the human disease (cognitive decline, amyloid deposits, increase in phospho-tau). Our aim was to establish the model, which has exclusively been used with Wistar rats in the literature, in Long-Evans rats as well. Three months old male animals were treated with 2x1.5 mg/kg STZ or citrate buffer vehicle injected bilaterally into the lateral ventricles on days 1 and 3. Learning and memory capabilities of the rats were then tested in the following paradigms: five choice serial reaction time test (daily training, started from week 2 post surgery and lasting until the end of the experiment), novel object recognition test (at week 8), passive avoidance (at week 11) and Morris water-maze (at week 14). Besides, open-field activity (at 1 month) and elevated plus maze performance (at week 6) were also investigated. 15 weeks after the STZ treatment the animals were sacrificed and the brain phospho tau/tau protein ratio were determined by Western Blot technique. We couldn’t find any significant difference between the treated and the control groups in any of the assays, however, due to the low number of data (n=9 and n=8, respectively), no far-reaching conclusion can be drawn. Nevertheless, our findings suggest that the Long-Evans strain may be more resistant to the STZ treatment than the Wistar rats and higher doses may be needed to trigger pathological changes in these animals.

Additional Information

István Gyertyán, gyertyan.istvan@med.semmelweis-univ.hu

Bemutatás módja

Poszter

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4632

Start

13:05

End

13:08

Authors (legacy)

Attila Gáspár, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Aliz Judit Ernyey, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Anna Bekő, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania
Barbara Hutka, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Brigitta Tekla Tajti, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Bence Tamás Varga, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
Zoltán Zádori, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest
István Gyertyán, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest